Clinical Trial

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-04
Trial Details
NCT Number NCT07488065
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Atopic Dermatitis
Enrollment 90 participants
Start Date 2026-03-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08